专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08207110B2 ITL3 polypeptides and uses thereof 有权
标题翻译： ITL3多肽及其用途
公开(公告)号：US08207110B2
公开(公告)日：2012-06-26
申请号：US11661877
申请日：2005-09-01
申请人： Nicole Suciu-Foca , Luigi Scotto , Seunghee Kim-Schulze , George Vlad , Raffaello Cortesini
发明人： Nicole Suciu-Foca , Luigi Scotto , Seunghee Kim-Schulze , George Vlad , Raffaello Cortesini
IPC分类号： A61K38/00
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译：本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中该多肽是水溶性的。本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。

2. 发明申请

US20090202544A1 Methods of Treating Diseases by Targeting Silt3 审中-公开
标题翻译：通过靶向治疗疾病的方法3
公开(公告)号：US20090202544A1
公开(公告)日：2009-08-13
申请号：US12223496
申请日：2007-02-02
申请人： Nicole Suciu-Foca , George Vlad , Raffaello Cortesini
发明人： Nicole Suciu-Foca , George Vlad , Raffaello Cortesini
IPC分类号： A61K39/395 , A61K35/14 , C12Q1/68 , A61K31/7088 , C07H21/04
CPC分类号： C07K16/2803 , A61K35/14 , C07K14/70503 , C07K2319/30 , G01N33/57488
摘要： This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also provides the above method, further comprising administering an anti-ILT3 antibody to the subject. The invention also provides a method of treating a subject afflicted with a disease, comprising administering to the subject an anti-ILT3 antibody, thereby treating the subject. In one embodiment, the disease is chronic viral disease. In another embodiment, the disease is cancer.
摘要翻译：本发明提供一种治疗患有疾病的受试者的方法，包括从受试者中取出血液，处理所抽取的血液，以从血液中除去sILT3，并将经处理的血液返回给受试者，由此治疗患有疾病。本发明还提供了上述方法，其还包括对受试者施用抗ILT3抗体。本发明还提供了治疗患有疾病的受试者的方法，其包括向受试者施用抗ILT3抗体，从而治疗受试者。在一个实施方案中，该疾病是慢性病毒性疾病。在另一个实施方案中，该疾病是癌症。

3. 发明授权

US09696312B2 Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand 有权
公开(公告)号：US09696312B2
公开(公告)日：2017-07-04
申请号：US14342440
申请日：2012-09-04
申请人： Nicole Suciu-Foca , George Vlad , Chih-Chao Chang , Zhuoru Liu , Adriana Ioana Colovai
发明人： Nicole Suciu-Foca , George Vlad , Chih-Chao Chang , Zhuoru Liu , Adriana Ioana Colovai
IPC分类号： A61K47/48 , G01N33/574 , C07K16/28 , C07K14/705
CPC分类号： G01N33/57492 , A61K47/6801 , A61K47/6803 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K14/7051 , C07K16/28 , C07K16/2803 , C07K16/3061 , C07K2319/30 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C07K2319/74 , G01N33/57426 , G01N33/57484 , G01N2333/70503 , G01N2333/70596 , G01N2458/00 , G01N2800/52
摘要： The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.

4. 发明授权

US4818689A Late differentiation antigen associated with helper T lymphocyte function 失效
标题翻译：与辅助T淋巴细胞功能相关的晚分化抗原
公开(公告)号：US4818689A
公开(公告)日：1989-04-04
申请号：US752397
申请日：1985-07-05
申请人： Nicole Suciu-Foca , Donald W. King
发明人： Nicole Suciu-Foca , Donald W. King
IPC分类号： A61K38/00 , C07K16/28 , G01N33/53
CPC分类号： C07K16/28 , A61K38/00
摘要： A late differentiation antigen (LDA.sub.1) expressed by activated helper cells is described. LDA.sub.1 is a membrane protein recognized by a monoclonal antibody produced by immunizing mice with an alloreactive human T cell clone with helper function. LDA.sub.1 is expressed by helper T cells optionally 9 days after activation. Anti-LDA.sub.1 monoclonal antibody blocks T cell enhancement of B-cell immunoglobulin production. Thus, LDA.sub.1 is associated with helper T cell effector function. Methods of diagnosis and therapy based upon LDA.sub.1 are also described.
摘要翻译：描述了由活化的辅助细胞表达的晚期分化抗原（LDA1）。 LDA1是通过用具有辅助功能的同种异体反应性人T细胞克隆免疫小鼠产生的单克隆抗体识别的膜蛋白。活化后9天，辅助T细胞表达LDA1。抗LDA1单克隆抗体阻断B细胞免疫球蛋白产生的T细胞增强。因此，LDA1与辅助T细胞效应子功能相关。还描述了基于LDA1的诊断和治疗方法。

5. 发明申请

US20170327591A1 Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand 审中-公开
公开(公告)号：US20170327591A1
公开(公告)日：2017-11-16
申请号：US15609808
申请日：2017-05-31
申请人： Nicole Suciu-Foca , George Vlad , Chih-Chao Chang , Zhuoru Liu , Adriana Ioana Colovai
发明人： Nicole Suciu-Foca , George Vlad , Chih-Chao Chang , Zhuoru Liu , Adriana Ioana Colovai
IPC分类号： C07K16/30 , A61K47/68 , G01N33/574 , C07K16/28 , C07K14/725 , A61K39/00
摘要： The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.

6. 发明申请

US20120321623A1 ILT3 Polypeptides and Uses Thereof 有权
标题翻译： ILT3多肽及其用途
公开(公告)号：US20120321623A1
公开(公告)日：2012-12-20
申请号：US13480421
申请日：2012-05-24
申请人： Nicole Suciu-Foca , Luigi Scotto , Seunghee Kim-Schulze , George Vlad , Raffaello Cortesini
发明人： Nicole Suciu-Foca , Luigi Scotto , Seunghee Kim-Schulze , George Vlad , Raffaello Cortesini
IPC分类号： A61K38/17 , C07K19/00 , C12N5/0783 , A61P37/06 , A61K39/395
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译：本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中该多肽是水溶性的。本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。

7. 发明申请

US20090274685A1 ILT3 POLYPEPTIDES AND USES THEREOF 有权
标题翻译： ILT3多肽及其用途
公开(公告)号：US20090274685A1
公开(公告)日：2009-11-05
申请号：US12419824
申请日：2009-04-07
申请人： NICOLE SUCIU-FOCA , GEORGE VLAD , RAFFAELLO CORTESINI
发明人： NICOLE SUCIU-FOCA , GEORGE VLAD , RAFFAELLO CORTESINI
IPC分类号： A61K39/395
CPC分类号： C07K14/70503 , A61K38/1774 , A61K39/001 , A61K45/06 , C07K2319/30
摘要： This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
摘要翻译：本发明提供了一种抑制移植胰岛细胞排斥反应的方法，包括向受试者施用包含全部或部分ILT3细胞外结构域的多肽，其中多肽是水溶性的。本发明进一步提供了一种治疗糖尿病的方法，其通过向受试者施用多肽来抑制移植的胰岛细胞的排斥。

8. 发明申请

US20080311073A1 Ilt3 Polypeptides and Uses Thereof 有权
标题翻译： Ilt3多肽及其用途
公开(公告)号：US20080311073A1
公开(公告)日：2008-12-18
申请号：US11661877
申请日：2005-09-01
申请人： Nicole Suciu-Foca , Luigi Scotto , Seunghee Kim-Schulze , George Vlad , Raffaello Cortesini
发明人： Nicole Suciu-Foca , Luigi Scotto , Seunghee Kim-Schulze , George Vlad , Raffaello Cortesini
IPC分类号： A61K45/00 , C07K14/00 , C12N15/11 , C12N15/00 , A61P37/00 , A61K35/12 , C12N5/06 , C12P21/04
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译：本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中该多肽是水溶性的。本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。

9. 发明授权

US06759239B2 Methods for generating tolerogenic antigen presenting cells 失效
标题翻译：产生耐受性抗原呈递细胞的方法
公开(公告)号：US06759239B2
公开(公告)日：2004-07-06
申请号：US09746311
申请日：2000-12-21
申请人： Nicole Suciu-Foca , Raffaello Cortesini , Zhuoru Liu , Chih-Chao Chang
发明人： Nicole Suciu-Foca , Raffaello Cortesini , Zhuoru Liu , Chih-Chao Chang
IPC分类号： C12N500
CPC分类号： G01N33/56972 , A61K35/12 , A61K39/001 , A61K2035/124 , A61K2039/5156 , C12N2510/00
摘要： This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.
摘要翻译：本发明提供了产生抗原特异性异体人抑制因子CD8 + CD28-T细胞的方法。本发明还提供了产生异种人抑制CD8 + CD28-T细胞的方法。本发明还提供了产生抗原特异性抗体抑制剂CD8 + CD28-T细胞的方法。使用如此产生的人抑制剂CD8 + CD28-T细胞降低同种异体移植物和异种移植物和自身免疫疾病排斥风险的治疗方法也提供了预防排斥反应和自身免疫性疾病的方法以及包含所产生的抑制性T细胞的疫苗。提供诊断方法以确定免疫抑制剂治疗水平是否需要减少。

10. 发明授权

US06667175B1 Generation of antigen specific T suppressor cells for treatment of rejection 失效
标题翻译：产生用于治疗排斥反应的抗原特异性T抑制细胞
公开(公告)号：US06667175B1
公开(公告)日：2003-12-23
申请号：US09333809
申请日：1999-06-15
申请人： Nicole Suciu-Foca
发明人： Nicole Suciu-Foca
IPC分类号： C12N500
CPC分类号： G01N33/56972 , A61K35/12 , A61K39/001 , A61K2035/124 , A61K2039/5156 , C12N2510/00
摘要： This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.
摘要翻译：本发明提供了产生抗原特异性异体人抑制因子CD8 + CD28-T细胞的方法。本发明还提供了产生异种人抑制CD8 + CD28-T细胞的方法。本发明还提供了产生抗原特异性抗体抑制剂CD8 + CD28-T细胞的方法。使用如此产生的人抑制剂CD8 + CD28-T细胞降低同种异体移植物和异种移植物和自身免疫疾病排斥风险的治疗方法也提供了预防排斥反应和自身免疫性疾病的方法以及包含所产生的抑制性T细胞的疫苗。提供诊断方法以确定免疫抑制剂治疗水平是否需要减少。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式